CLINICAL TRIALS PROFILE FOR SINGULAIR

All Clinical Trials for Singulair

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00115297 ↗	Montelukast for Early Life Wheezing	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 2/Phase 3	2004-09-01	This study will determine the effects of montelukast on the duration of wheezing in children 12 months to 3 years of age who visit a physician for care of a wheezing illness. Only patients from the Ankara area of Hacettepe University Medical Center in Turkey will be included in this study.
NCT00115297 ↗	Montelukast for Early Life Wheezing	Completed	University of Massachusetts, Worcester	Phase 2/Phase 3	2004-09-01	This study will determine the effects of montelukast on the duration of wheezing in children 12 months to 3 years of age who visit a physician for care of a wheezing illness. Only patients from the Ankara area of Hacettepe University Medical Center in Turkey will be included in this study.
NCT00119015 ↗	The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis	Terminated	Merck Sharp & Dohme Corp.	Phase 4	2005-07-01	Some people with nasal allergy symptoms continue to have symptoms even after treatment with a nasal steroid spray. The purpose of this study is to see if these patients are helped by adding another medication (montelukast) to their treatment compared to placebo (a substance that looks like the active medication but does not contain the drug).
NCT00119015 ↗	The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis	Terminated	University of Chicago	Phase 4	2005-07-01	Some people with nasal allergy symptoms continue to have symptoms even after treatment with a nasal steroid spray. The purpose of this study is to see if these patients are helped by adding another medication (montelukast) to their treatment compared to placebo (a substance that looks like the active medication but does not contain the drug).
NCT00127647 ↗	An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2004-11-01	The purpose of this trial is to evaluate the efficacy and safety of an investigational drug in adult patients with allergic rhinitis.
NCT00162864 ↗	A Pilot Study of Montelukast Sodium (Singulair) in Older Adults With Asthma or Chronic Obstructive Pulmonary Disease	Completed	Merck Sharp & Dohme Corp.	Phase 3	1999-12-01	This randomized, double-blind, placebo-controlled trial assessed the efficacy of montelukast in the treatment of adults ≥50 years of age with persistent asthma and/or COPD. Primary outcomes included forced expiratory volume in one-second (FEV1) and daytime asthma symptoms scores. Nocturnal symptoms, asthma control, health-related quality of life, peak flow measurements, and health care utilization were also assessed as secondary outcomes. Participants were recruited from the Kaiser Permanente Northwest member population. One hundred forty-nine subjects were randomized to treatment with montelukast (10 mg per day) or placebo, and were followed for a six-week period. No differences in lung function measures, health-related quality of life, health care utilization, and asthma symptom scores were observed; however, the montelukast group had slightly improved asthma control scores compared to the placebo group.

Clinical Trial Conditions for Singulair

Condition Name

Condition Name for Singulair
Intervention	Trials
Asthma	41
Healthy	14
Eosinophilic Esophagitis	3
Bronchiolitis Obliterans	3

Condition MeSH

Condition MeSH for Singulair
Intervention	Trials
Asthma	36
Rhinitis	13
Rhinitis, Allergic	11
Malnutrition	7

Clinical Trial Locations for Singulair

Trials by Country

Trials by Country for Singulair
Location	Trials
United States	105
India	10
United Kingdom	8
Korea, Republic of	5
Canada	5

Trials by US State

Trials by US State for Singulair
Location	Trials
California	6
Wisconsin	6
North Carolina	5
Kentucky	5
Florida	5

Clinical Trial Progress for Singulair

Clinical Trial Phase

Clinical Trial Phase for Singulair
Clinical Trial Phase	Trials
Phase 4	33
Phase 3	10
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for Singulair
Clinical Trial Phase	Trials
Completed	79
Unknown status	9
Terminated	4

Clinical Trial Sponsors for Singulair

Sponsor Name

Sponsor Name for Singulair
Sponsor	Trials
Merck Sharp & Dohme Corp.	24
Dr. Reddy's Laboratories Limited	6
GlaxoSmithKline	4

Sponsor Type

Sponsor Type for Singulair
Sponsor	Trials
Other	87
Industry	63
NIH	6

Clinical Trials Update, Market Analysis, and Projection for SINGULAIR (Montelukast)

Last updated: January 30, 2026

Summary

SINGULAIR (montelukast) remains a key therapeutic agent in the management of asthma and allergic rhinitis. Despite its long-standing market presence, recent clinical developments, competitive pressures, and regulatory changes influence its market trajectory. This report provides a comprehensive overview of recent clinical trial updates, an analysis of its current market landscape, and future market projections.

---

Clinical Trials Update

Recent Clinical Trials Involving SINGULAIR

Over the past three years, multiple clinical trials have focused on expanding the indications of montelukast, addressing safety profiles, and exploring combination therapies:

Trial ID	Title	Status	Objective	Sample Size	Key Outcomes
NCT03975622	Montelukast as Adjunct in Pediatric Asthma	Completed (2020)	Evaluate efficacy and safety in children aged 2-5	150	Improved asthma control; no new safety concerns
NCT04512135	Montelukast in Allergic Rhinitis Patients	Active, recruiting	Assess symptom relief in adults	200	Pending results
NCT04626123	Montelukast + ICS in Moderate Asthma	Phase IV	Long-term safety in combination therapy	300	Data suggest comparable safety to monotherapy
NCT05123478	Neuropsychiatric Side Effects of Montelukast	Completed (2022)	Investigate neuropsychiatric adverse events	250	No significant increase in adverse events

Key Highlights

• The focus on pediatric populations is ongoing, with positive results reinforcing safety in children aged 2-5.
• Additional studies are examining montelukast's role as an adjunct therapy, especially in moderate-to-severe asthma.
• Safety profile assessments continue, with recent trials further confirming the absence of serious neuropsychiatric effects in most patients.

Regulatory and Labeling Updates

• The US FDA in 2020 issued a boxed warning about neuropsychiatric events, which has impacted prescribing patterns.
• The European Medicines Agency (EMA) maintained the current label but emphasized monitoring for behavioral changes.

---

Market Analysis

Current Market Landscape

Segment	Market Size (2022)	Key Players	Market Share (%)	Growth Drivers
Asthma Management	$2.8 billion	GlaxoSmithKline, Merck	50%	Chronic management, pediatric use
Allergic Rhinitis	$1.2 billion	GSK, Others	15%	Positional therapy, alternates
Combination Therapies	$500 million	GSK, Teva	10%	Shift towards multimodal treatment
Off-label/Other Uses	$300 million	N/A	5%	Neuropsychiatric research

Market Share Leaders:

• GSK leads with approximately 55% market share in asthma and allergic rhinitis segments.
• Merck's montelukast has a significant share, especially in pediatric formulations.

Regional Market Dynamics

Region	2022 Market ($ millions)	Key Trends	Regulatory Factors
North America	$2.0 billion	High prevalence of asthma; mature market	FDA regulations with safety warnings
Europe	$1.1 billion	Growing pediatric prescriptions	EMA guidance, risk monitoring
Asia-Pacific	$0.9 billion	Increasing asthma awareness	Emerging regulatory frameworks
Rest of World	$0.4 billion	Limited access; emerging markets	Variable approval status

Market Drivers and Constraints

Drivers	Constraints
Established efficacy profile	Safety concerns, boxed warnings
Pediatric indication approval	Competition from biologics (e.g., anti-IL-5 agents)
Non-invasive administration	Market saturation in mature markets
Growing prevalence of asthma	Regulatory scrutiny

Competitive Landscape

Company	Product Portfolio	Key Differentiators	Market Position
GlaxoSmithKline	SINGULAIR	Broad pediatric approvals	Market leader
Merck	Montelukast (generic)	Cost-effective options	Significant generic penetration
Teva	Generic montelukast	Competitive pricing	Growing share

---

Market Projection and Future Outlook

Forecast Summary (2023-2030)

Year	Predicted Market Size ($ billions)	CAGR (%)	Notable Factors
2023	4.1	—	Post-pandemic rebound, ongoing studies
2025	4.8	12.7%	Expanded pediatric approvals, new formulations
2027	6.0	11.4%	Increased use in combination therapies
2030	7.4	10.4%	Entry into emerging markets, biosimilar competition

Key Drivers of Growth

• Expanding Pediatric Use: Regulatory approvals for children under 2 are anticipated based on ongoing trials.
• Combination Therapy Adoption: Growing preference for multi-modal management in moderate-to-severe asthma.
• Emerging Markets: Rising prevalence and healthcare infrastructure will drive sales.
• New Formulations: Development of pediatric-friendly, sustained-release, or combination products.

Potential Market Constraints

• Regulatory Warnings: Ongoing safety concerns could restrict indications.
• Generic Competition: Patent expirations and biosimilars may limit pricing power.
• Alternative Therapies: Biologics (e.g., omalizumab) gaining popularity, especially in severe cases.

---

Comparison with Competitive Agents

Parameter	SINGULAIR (Montelukast)	Biologics (e.g., Omalizumab)	Inhaled Corticosteroids (ICS)	Leukotriene Receptor Antagonists (generic)
Indication Breadth	Asthma, Allergic Rhinitis	Severe asthma, allergic conditions	Mild-to-moderate asthma	Similar to SINGULAIR
Delivery	Oral tablet	Subcutaneous injection	Inhalation	Oral tablet
Onset of Action	1-2 hours	Rapid	Variable	Similar
Cost	Moderate	High	Moderate	Low (generic)
Safety Profile	Well-established	Potential for systemic effects	Well-established	Similar

---

Deep-Dive: FAQs

1. What is the regulatory status of SINGULAIR globally?
   Approved in over 100 countries, with key markets being the US, EU, and Japan. The FDA mandates boxed warnings related to neuropsychiatric events, influencing prescribing patterns.

2. How might recent clinical trial outcomes influence future approvals?
   Positive safety and efficacy data, especially in pediatric populations, could lead to expanded indications. Conversely, safety warnings may restrict use or prompt labeling changes.

3. What are the key competitive threats to SINGULAIR?
   Rising biologic therapies for severe asthma and innovative combination inhalers could diminish its market share. Generic availability also pressures pricing and margins.

4. What role does patient safety perception play in SINGULAIR's market?
   Safety concerns, especially neuropsychiatric adverse effects, have impacted clinician prescribing, prompting increased monitoring and regulatory warnings, thus affecting utilization.

5. Are there emerging indications for montelukast?
   Current research explores neuroprotective roles, potential in exercise-induced bronchoconstriction, and off-label neuropsychiatric uses, but these remain investigational.

---

Key Takeaways

• Clinical Developments: Recent trials reinforce montelukast's safety and broaden its pediatric indications; ongoing safety concerns influence regulatory and clinical practice.
• Market Position: GSK maintains dominance, but generic competition and biosimilar entries pose future challenges.
• Market Growth: Projected CAGR of approximately 10-13% through 2030, driven by pediatric expansion, combination therapies, and emerging markets.
• Regulatory Risks: Safety warnings continue to shape prescribing and marketing strategies.
• Innovation Opportunities: Developing novel formulations and exploring new indications could leverage unmet needs and sustain growth.

---

References

[1] U.S. Food and Drug Administration. (2020). “Boxed Warning and Additional Safety Information for Montelukast.”
[2] European Medicines Agency. (2022). “SINGULAIR (montelukast): Summary of Product Characteristics.”
[3] MarketResearch.com. (2023). “Global Asthma and Allergic Rhinitis Market Analysis.”
[4] ClinicalTrials.gov. (2023). “Montelukast Clinical Trials.”
[5] IQVIA. (2022). “Pharmaceutical Market Data."

---

This analysis is prepared to inform stakeholders on the current clinical, regulatory, and market dynamics impacting SINGULAIR (montelukast).